Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults From Ritonavir Boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial

NCT04229290 is registered in ClinicalTrials.gov with University of Nairobi as lead sponsor.

NCT NCT04229290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults From Ritonavir Boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial
Lead sponsor
University of Nairobi
Phase
Phase 4
Overall status
Completed
Start date
February 12, 2020
Completion date
September 16, 2021
Enrollment
795 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection